Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription 15.12.2025 2 Am J Clin Oncol 12 Ann Surg Oncol 7 BMC Cancer 1 Br J Cancer 2 Breast Cancer 4 Breast Cancer (Dove Med Press) 10 Breast Cancer Res 16 Breast Cancer Res Treat 1 Breast J 3 Cancer 2 Cancer Cell 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Carcinogenesis 3 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 3 Eur J Surg Oncol 1 Eur Radiol 1 Exp Cell Res 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Clin Invest 2 J Clin Oncol 4 J Natl Cancer Inst 4 J Nucl Med 2 J Pathol 3 JAMA 1 Mol Ther Oncol 1 N Engl J Med 1 Nature 8 NPJ Breast Cancer 1 Oncology 1 PLoS Biol 5 PLoS One 2 Proc Natl Acad Sci U S A 1 Radiol Imaging Cancer 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. DRANITSARIS G, Neuhalfen H, Seifter N, Peevyhouse A, et al
   Disparities in Biopsy Practice in Metastatic Breast Cancer Patients Managed in Community Oncology Practices in the United States: Implications for Guideline-Concordant Care.
   Am J Clin Oncol. 2025 Dec 4. doi: 10.1097/COC.0000000000001281.
   PubMed         Abstract available
   
   
2. QURESHI Z, Jamil A, Kahlon N, Hameed F, et al
   Targeted and Chemo-Free Approaches in HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis.
   Am J Clin Oncol. 2025 Dec 9. doi: 10.1097/COC.0000000000001285.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. HANS M, Tamaskar AS, Recko A, Bychkovsky BL, et al
   ASO Visual Abstract: Evaluating the Implementation and Maintenance of a Breast Cancer Risk Assessment and Prevention Program.
   Ann Surg Oncol. 2025 Dec 13. doi: 10.1245/s10434-025-18844.
   PubMed        
   
   
4. BARMETTLER G, Leonard S, Giannakou A, Park KU, et al
   Breast Cancer Presentation and Treatment Patterns in Sexual and Gender Minorities.
   Ann Surg Oncol. 2025 Dec 11. doi: 10.1245/s10434-025-18853.
   PubMed         Abstract available
   
   
5. COBB AN, Dong X, Makope A, Cohen L, et al
   ASO Visual Abstract: Contemporary Nodal Management and Overall Survival in Older Patients with HR-/HER2+ Breast Cancer.
   Ann Surg Oncol. 2025 Dec 8. doi: 10.1245/s10434-025-18836.
   PubMed        
   
   
6. LEE K, Pallesi A, Valdez BJ, Hanes DA, et al
   Factors Associated With Residual Disease on Re-Excision Specimens After Breast-Conserving Surgery for Breast Cancer.
   Ann Surg Oncol. 2025 Dec 6. doi: 10.1245/s10434-025-18813.
   PubMed         Abstract available
   
   
7. DOUGLAS SR, Thomas SM, Chiba A, DiNome ML, et al
   ASO Visual Abstract: Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery.
   Ann Surg Oncol. 2025 Dec 4. doi: 10.1245/s10434-025-18393.
   PubMed        
   
   
8. MELANSON A, Mashal S, Apostolova C, Ferroum A, et al
   Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of Age.
   Ann Surg Oncol. 2026;33:108-117.
   PubMed         Abstract available
   
   
9. WANG J, Shammas RL, Graziano FD, Boe LA, et al
   One or Two Drains? A Propensity Score-Matched Analysis of Postoperative Complications After Tissue Expander Placement.
   Ann Surg Oncol. 2026;33:668-675.
   PubMed         Abstract available
   
   
10. BROWN S, Shen Y, Klimitz FJ, Nair M, et al
    Immediate Lymphatic Reconstruction (ILR) for the Prevention of Lymphedema: A Meta-analysis of Prospective Clinical Trials.
    Ann Surg Oncol. 2026;33:60-76.
    PubMed         Abstract available
    
    
11. OZAWA N, Takeyama E, Sakai H, Katayama A, et al
    Molecular and Biological Features of Invasive Lobular Carcinoma: Toward New Treatment Strategies.
    Ann Surg Oncol. 2026;33:146-158.
    PubMed         Abstract available
    
    
12. NAASEH A, Bewley AF, Nickel KB, Myckatyn TM, et al
    Impact of Sociodemographic and Clinical Factors on Postoperative Outcomes Following Immediate Postmastectomy Autologous Breast Reconstruction.
    Ann Surg Oncol. 2026;33:658-667.
    PubMed         Abstract available
    
    
13. CHANDLER JM, Kim M, Sevilimedu V, Le TV, et al
    Trends in Patient-Reported Outcomes After Breast-Conserving Surgery and Partial-Breast Versus Whole-Breast Irradiation.
    Ann Surg Oncol. 2026;33:50-59.
    PubMed         Abstract available
    
    
14. ZAVERI S, Sun SX, Bevers TB, Albarracin CT, et al
    Implications of the COMET Trial for the Management of Atypical Ductal Hyperplasia.
    Ann Surg Oncol. 2026;33:43-49.
    PubMed         Abstract available
    
    

    
    BMC Cancer

15. ANDRADE DC, Parrish L, Harriss C, Peterson LL, et al
    A qualitative exploration of patient and clinician needs and preferences for a physical activity intervention during breast cancer chemotherapy.
    BMC Cancer. 2025 Dec 12. doi: 10.1186/s12885-025-15342.
    PubMed         Abstract available
    
    
16. FESSI Z, Bonnier S, Lodyga K, Wallet J, et al
    Stereotactic re-irradiation for lymph node recurrence of breast cancer.
    BMC Cancer. 2025 Dec 8. doi: 10.1186/s12885-025-15418.
    PubMed        
    
    
17. HUANG H, Chen X, Wang Z, Zhang Y, et al
    Evidence-based prescription: optimal exercise type and dose for pain management in breast cancer survivors-a systematic review and dose-response network meta-analysis.
    BMC Cancer. 2025 Dec 6. doi: 10.1186/s12885-025-15432.
    PubMed         Abstract available
    
    
18. ALLSOPP RC, Page K, Wren E, Nteliopoulos G, et al
    Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
    BMC Cancer. 2025;25:1858.
    PubMed         Abstract available
    
    
19. CAGDAS EK, Cagdas B
    LYN mutations in breast cancer: hypothesis-generating evidence for an association with central nervous system metastasis and domain-level insights.
    BMC Cancer. 2025 Dec 5. doi: 10.1186/s12885-025-15398.
    PubMed         Abstract available
    
    
20. YANG Y, Ma Y, Xue F, Li J, et al
    Using single-cell and transcriptome data to identify prognostic genes associated with SUMO-ylation and their molecular regulatory mechanisms in breast cancer.
    BMC Cancer. 2025 Dec 6. doi: 10.1186/s12885-025-15265.
    PubMed         Abstract available
    
    
21. SPERK E, Lemanski C, Neumaier C, Lauer J, et al
    Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E.
    BMC Cancer. 2025;25:1862.
    PubMed         Abstract available
    
    

    
    Br J Cancer

22. MA J, Sun S, Tang X, Wang J, et al
    Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.
    Br J Cancer. 2025 Dec 9. doi: 10.1038/s41416-025-03287.
    PubMed         Abstract available
    
    

    
    Breast Cancer

23. SHEN T, Ye D, Deng P, Yao M, et al
    Kinetic heterogeneity is associated with axillary lymph node metastasis in cN0 breast cancer based on dynamic contrast-enhanced magnetic resonance imaging radiomics nomogram.
    Breast Cancer. 2025 Dec 10. doi: 10.1007/s12282-025-01805.
    PubMed        
    
    
24. OKA T, Nakagomi H, Kimura A, Furuya K, et al
    Key issues in surveillance of secondary breast cancer.
    Breast Cancer. 2025 Dec 10. doi: 10.1007/s12282-025-01809.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

25. BOWER J, Anwar A, Chaudhary J, Chen Z, et al
    Dual Receptor Targeting Ensures Uptake and Anticancer Efficacy of Low-Density Lipoprotein-Docosahexaenoic Acid Nanoparticles Across Breast Cancer Cell Subtypes.
    Breast Cancer (Dove Med Press). 2025;17:1159-1182.
    PubMed         Abstract available
    
    
26. GUO M, Chang Y, Dai Y, Liu X, et al
    Circular RNA DENND4C Regulates Cell Malignant Behaviors in Breast Cancer Through the miR-26a-5p/HSPA8 Axis.
    Breast Cancer (Dove Med Press). 2025;17:1145-1157.
    PubMed         Abstract available
    
    
27. HONG M, Huang X, Xu Q, Ma Z, et al
    Tissue- and Cell-Type-Specific Genetic Regulation of CTBP1 in Breast Cancer: Integrative Analyses with Exploratory Single-Cell and Imaging Data.
    Breast Cancer (Dove Med Press). 2025;17:1133-1143.
    PubMed         Abstract available
    
    
28. QIU Q, Chen C, Chen J, Liao C, et al
    Development and Validation of a Radiomics-Based Nomogram for Predicting HER-2 Status in Breast Cancer: A Retrospective Study with Small Validation Cohort.
    Breast Cancer (Dove Med Press). 2025;17:1119-1132.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

29. ALIM R, Akalanka HMK
    Metformin and its derivatives in breast cancer: from glycaemic control to tumor-intrinsic pathways.
    Breast Cancer Res. 2025 Dec 12. doi: 10.1186/s13058-025-02194.
    PubMed         Abstract available
    
    
30. WANG X, Zhou Q, Wang P, Bao S, et al
    Nuclear PD-L1 drives IFN-gamma-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E.
    Breast Cancer Res. 2025 Dec 12. doi: 10.1186/s13058-025-02193.
    PubMed         Abstract available
    
    
31. KUBECZKO M, d'Amico A, Chrabanski O, Handkiewicz-Junak D, et al
    Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.
    Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02191.
    PubMed        
    
    
32. NASRAZADANI A, Tidwell RS, Kai M, Lim B, et al
    Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition.
    Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02162.
    PubMed         Abstract available
    
    
33. DE LA FUENTE LR, Law AMK, Rangel-Sanchez L, Venhuizen J, et al
    Modelling the metastatic immune microenvironment in triple-negative breast cancer.
    Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02186.
    PubMed         Abstract available
    
    
34. YANG L, An M, Song H, Zhang X, et al
    Multidimensional cell-free DNA fragmentomics enables early detection of breast cancer.
    Breast Cancer Res. 2025 Dec 9. doi: 10.1186/s13058-025-02190.
    PubMed         Abstract available
    
    
35. SCHREURS MAC, Timmermans AM, Carpenter MA, Smid M, et al
    APOBEC3B protein expression associates with poor prognosis for breast cancer patients with ER-positive disease.
    Breast Cancer Res. 2025 Dec 9. doi: 10.1186/s13058-025-02167.
    PubMed        
    
    
36. HE M, Song K, Luo Y, Lai G, et al
    Integrative multi-omics reveals common and distinct pathogenic mechanisms and preoperative diagnostic signatures in breast fibroepithelial lesions.
    Breast Cancer Res. 2025;27:214.
    PubMed         Abstract available
    
    
37. ZHANG W, Zhang S, You J, Li F, et al
    Attention-based multimodal fusion transformer for predicting the efficacy of neoadjuvant therapy in breast cancer: a cross-institutional retrospective study.
    Breast Cancer Res. 2025 Dec 6. doi: 10.1186/s13058-025-02181.
    PubMed         Abstract available
    
    
38. HSU L, Siegel J, Nasarre P, Oberholtzer N, et al
    Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-Upsilon reprograms tumor-associated macrophages to suppress triple negative breast cancer.
    Breast Cancer Res. 2025;27:209.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

39. CHENG H, Gong J, Yu L, Feng X, et al
    Compression sleeves for prevention and treatment of breast cancer-related lymphedema: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2025;215:41.
    PubMed         Abstract available
    
    
40. WOOSTER M, DeStephano D, Beauchemin M, Wang S, et al
    Disparities in delays and outcomes in patients with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2025;215:37.
    PubMed         Abstract available
    
    
41. YEN TWF, Canales B, McGinley EL, Tarima S, et al
    The association of contemporary mortgage lending bias and receipt of guideline-concordant systemic treatment among older women with breast cancer.
    Breast Cancer Res Treat. 2025;215:40.
    PubMed         Abstract available
    
    
42. FERRI GM, Martinez CB, Acevedo J, Bhatt S, et al
    Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors.
    Breast Cancer Res Treat. 2025;215:36.
    PubMed         Abstract available
    
    
43. SADIA K, Talia T, Hussain I, Chaudhry M, et al
    Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2025;215:39.
    PubMed         Abstract available
    
    
44. YANG Z, Qing M, Zhang Y, Wu J, et al
    Risk factors for postoperative bleeding following breast cancer surgery: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2025;215:38.
    PubMed         Abstract available
    
    
45. GREENBERG MR, Noveihed A, George M
    Overview of ocular toxicities associated with breast cancer therapies.
    Breast Cancer Res Treat. 2025;215:33.
    PubMed         Abstract available
    
    
46. PAGE K, Martinson LJ, Hastings RK, Acheampong E, et al
    Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
    Breast Cancer Res Treat. 2025;215:34.
    PubMed         Abstract available
    
    
47. ZUBROWSKA J, Pieniazek M, Polakiewicz-Gilowska A, Malejcikova M, et al
    Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study.
    Breast Cancer Res Treat. 2025;215:35.
    PubMed         Abstract available
    
    
48. WIEDER V, Engel J, Eichstadt K, Kaufhold S, et al
    Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer.
    Breast Cancer Res Treat. 2025;215:31.
    PubMed         Abstract available
    
    
49. ASHOK KUMAR P, Ghelani G, Koorapati G, Paulraj S, et al
    The impact of adjuvant chemotherapy on overall survival in premenopausal (age
    Breast Cancer Res Treat. 2025;215:32.
    PubMed         Abstract available
    
    
50. RADWAN E, Memoli V, Seguin L, Mancini J, et al
    Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study.
    Breast Cancer Res Treat. 2025;215:30.
    PubMed         Abstract available
    
    
51. JARA P, Ariant M, Jimenez R, Bringas M, et al
    Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.
    Breast Cancer Res Treat. 2025;215:28.
    PubMed         Abstract available
    
    
52. KAKANI P, Ro V, McGuinness JE, Michel A, et al
    Factors associated with receipt of surveillance breast MRI among racially and ethnically diverse women with operable breast cancer.
    Breast Cancer Res Treat. 2025;215:27.
    PubMed         Abstract available
    
    
53. LAPERCHE-SANTOS D, Assad-Suzuki D, Resende H, Moura FC, et al
    Impact of public vs. private insurance coverage on quality of life of women with early-stage estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2025;215:26.
    PubMed         Abstract available
    
    
54. DEDEEPYA SD, Goel V, Desai NN
    Comment on "Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis".
    Breast Cancer Res Treat. 2025;215:29.
    PubMed         Abstract available
    
    

    
    Breast J

55. VAND BEILANKOUHI EA, Kheradi N, Vaez-Gharamaleki Y, Roshani S, et al
    Examining the Role of Matrix Metalloproteinase-2 and MicroRNAs Regulation in Breast Cancer.
    Breast J. 2025;2025:8816789.
    PubMed         Abstract available
    
    

    
    Cancer

56. ALLER A, Zhu S, Lyon L, Habel LA, et al
    Is age just a number? Oncotype DX testing and chemotherapy use in the post-TAILORx era.
    Cancer. 2025;131:e70218.
    PubMed         Abstract available
    
    
57. LUIJENDIJK MJ, Lee Meeuw Kjoe PR, Wortelboer N, van Ommen-Nijhof A, et al
    Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancer.
    Cancer. 2025;131:e70212.
    PubMed         Abstract available
    
    
58. MOUNA BM, Batra A, Sharma V, Kataria B, et al
    Metformin with neoadjuvant chemotherapy in localized triple-negative and Her2neu-positive breast cancer: A prospective phase 2 open-label randomized controlled trial (McBETH).
    Cancer. 2025;131:e70205.
    PubMed         Abstract available
    
    

    
    Cancer Cell

59. FAN L, Zhang WJ, Li HP, Zeng XH, et al
    Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
    Cancer Cell. 2025 Dec 4:S1535-6108(25)00496-9. doi: 10.1016/j.ccell.2025.
    PubMed         Abstract available
    
    
60. MIGLIOZZI S, Adabbo B, Garofano L, Wu F, et al
    Restraint of cancer cell plasticity by spatial homotypic clustering.
    Cancer Cell. 2025;43:2206-2223.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

61. SAMBE T, Imamura CK, Hida N, Yamazaki T, et al
    Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer.
    Cancer Chemother Pharmacol. 2025;95:123.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

62. LI X, Shan Y, Yu Y, Zhang D, et al
    Negative emotions and breast cancer risk for women with benign breast disease: a prospective multicenter cohort study in China.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Lett

63. YOU Y, Wei L, Dai M, Zhao G, et al
    BMP9 potentiates immunotherapy in triple-negative breast cancer by suppressing Tregs infiltration via the PRKDC-CCL2 axis.
    Cancer Lett. 2025;639:218175.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

64. 
    Correction to: Triple-negative breast cancer molecular subtypes and potential detection targets for biological therapy indications.
    Carcinogenesis. 2025;46:bgaf086.
    PubMed        
    
    

    
    Clin Breast Cancer

65. KRAMER G, Volders J, den Haring F, Opperman R, et al
    National Breast Cancer Surgery Snapshot Study: Breast Cancer Surgery after Neoadjuvant Systemic Therapy in Primary Breast Cancer (MANS Study).
    Clin Breast Cancer. 2025;26:64-72.
    PubMed         Abstract available
    
    
66. SMYTH NM, Zaborowski AM, Bolarinwa BV, Hembrecht S, et al
    Do Not Rush to Omit Sentinel Lymph Node Biopsy for Early Breast Cancer Patients.
    Clin Breast Cancer. 2025;26:58-63.
    PubMed         Abstract available
    
    
67. KRAMER GM, Heeling E, Volders JH, Peeters MTFDV, et al
    Enhancing Breast Cancer Research Through Snapshot Studies: Benefits and Challenges.
    Clin Breast Cancer. 2025;26:50-57.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

68. MARTIN M, Guerrero-Zotano AL, Perez-Lopez ME, Ruiz-Borrego M, et al
    Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.
    Clin Cancer Res. 2025 Dec 12. doi: 10.1158/1078-0432.CCR-25-2435.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

69. BORREGO MR, Lopez-Bravo DP, Vila MM, Perez-Garcia JM, et al
    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
    Eur J Cancer. 2025;233:116161.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

70. SHAH S, Manor KA, Shaker H, Harvey J, et al
    Breast Cancer After Breast Augmentation study (BCABA): A national multicentre collaborative study of patient management and outcomes.
    Eur J Surg Oncol. 2025;52:111306.
    PubMed         Abstract available
    
    
71. KIM KJ, Kang E, Baek SH, Lee HB, et al
    Alteration in estrogen receptor status in metachronous contralateral breast cancer among unilateral early breast cancer patients with BRCA 1/2 mutations.
    Eur J Surg Oncol. 2025;52:111332.
    PubMed         Abstract available
    
    
72. ADDIE M, Miron AD, Iny E, Wong SM, et al
    Patients with positive axillary nodes undergoing upfront surgery: Can axillary dissection be safely omitted?
    Eur J Surg Oncol. 2026;52:111304.
    PubMed         Abstract available
    
    

    
    Eur Radiol

73. NOGUEIRA L, Adubeiro N, Nunes RG
    Changing slopes: can we be moving toward improved early treatment response prediction in breast cancer?
    Eur Radiol. 2025 Dec 5. doi: 10.1007/s00330-025-12204.
    PubMed        
    
    

    
    Exp Cell Res

74. ALIREZAE P, Khoshraftar SH, Hadi S, Amirfiroozi A, et al
    Navigating the Nexus: Dysregulation of Non-Coding RNAs in Breast Cancer Under Therapeutic Interventions - Mechanisms and Clinical Implications.
    Exp Cell Res. 2025 Dec 9:114854. doi: 10.1016/j.yexcr.2025.114854.
    PubMed         Abstract available
    
    

    
    Int J Cancer

75. PINO-ROSON C, Avila-Arroyo S, Parra-Blazquez D, Soto Zabalgogeazcoa MJ, et al
    Breast cancer incidence and survival by subtype, stage at diagnosis and socioeconomic deprivation among young women in the Community of Madrid, Spain.
    Int J Cancer. 2025 Dec 5. doi: 10.1002/ijc.70278.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

76. DAGAR A, Ghosh A, Singhal A, Kumar A, et al
    A study of curative approach treatment along with metastasis-directed SBRT in bone-only oligometastatic breast cancer.
    Int J Radiat Oncol Biol Phys. 2025 Dec 11:S0360-3016(25)06534.
    PubMed         Abstract available
    
    
77. BEYER S, Hawley J, Gokun Y, Yildiz VO, et al
    Use of MRI to Guide Pre-op APBI in the Prone Position and Treatment Response in Clinical Stage 1 Hormone Sensitive Breast Cancer: A Phase I/II Study.
    Int J Radiat Oncol Biol Phys. 2025 Dec 6:S0360-3016(25)06529.
    PubMed         Abstract available
    
    

    
    J Biol Chem

78. MAIER S, Schroth W, Mier F, Matt L, et al
    Tamoxifen metabolites acting via BK(Ca) orchestrate the dynamics of K(+) and Ca(2+) in breast cancer cells.
    J Biol Chem. 2025 Dec 6:111015. doi: 10.1016/j.jbc.2025.111015.
    PubMed         Abstract available
    
    

    
    J Clin Invest

79. NAPOLITANO F, Wang Y, Sudhan DR, Gonzalez-Ericsson PI, et al
    CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer.
    J Clin Invest. 2025 Dec 9:e188458. doi: 10.1172/JCI188458.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

80. DIERAS V, Curigliano G, Martin M, Lerebours F, et al
    HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
    J Clin Oncol. 2025 Dec 10:101200JCO2502600. doi: 10.1200/JCO-25-02600.
    PubMed         Abstract available
    
    
81. CHEN X, Huang J, Shi H, Zhu J, et al
    Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
    J Clin Oncol. 2025 Dec 9:JCO2502412. doi: 10.1200/JCO-25-02412.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

82. JOURQUIN J, Dickerson JC, Marks EG, Epps J, et al
    Susan G. Komen's ShareForCures(R): a patient-engaged, nationwide breast cancer research registry.
    J Natl Cancer Inst. 2025 Dec 13:djaf353. doi: 10.1093.
    PubMed         Abstract available
    
    
83. HU X, Cai C, Arshad S, Anderson JN, et al
    Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.
    J Natl Cancer Inst. 2025 Dec 9:djaf301. doi: 10.1093.
    PubMed         Abstract available
    
    
84. SHUMWAY DA, Corbin KS, Shiraishi S, Farah MH, et al
    Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation.
    J Natl Cancer Inst. 2025 Dec 6:djaf346. doi: 10.1093.
    PubMed         Abstract available
    
    
85. HAZELWOOD E, Goudswaard LJ, Lee MA, Vabistsevits M, et al
    Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.
    J Natl Cancer Inst. 2025;117:2621-2642.
    PubMed         Abstract available
    
    

    
    J Nucl Med

86. YEH R
    Reply: The Role of HER2 PET in Treatment of Breast Cancer.
    J Nucl Med. 2025 Dec 11:jnumed.125.271241. doi: 10.2967/jnumed.125.271241.
    PubMed        
    
    
87. SONG J, Ye J
    Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions.
    J Nucl Med. 2025 Dec 11:jnumed.125.271101. doi: 10.2967/jnumed.125.271101.
    PubMed        
    
    
88. BADING JR, Mortimer JE
    The Role of HER2 PET in Treatment of Breast Cancer.
    J Nucl Med. 2025 Dec 11:jnumed.125.271364. doi: 10.2967/jnumed.125.271364.
    PubMed        
    
    
89. SPECHT JM, van Geel JJL, Song S, Liu C, et al
    The Role of Estrogen Receptor-Targeted PET with 16alpha-(18)F-Fluoro-17beta-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis.
    J Nucl Med. 2025 Dec 4:jnumed.125.270763. doi: 10.2967/jnumed.125.270763.
    PubMed         Abstract available
    
    

    
    J Pathol

90. KADER T, Zethoven M, Mahale S, Saunders H, et al
    Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression.
    J Pathol. 2026;268:1-12.
    PubMed         Abstract available
    
    
91. NTELIOPOULOS G, Wren E, Rushton A, Wadsley MK, et al
    Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing.
    J Pathol. 2026;268:13-26.
    PubMed         Abstract available
    
    

    
    JAMA

92. 
    Risk-Based vs Annual Breast Cancer Screening: Research Summary.
    JAMA. 2025 Dec 12:e2524865. doi: 10.1001/jama.2025.24865.
    PubMed        
    
    
93. ESSERMAN LJ, Fiscalini AS, Naeim A, Van't Veer LJ, et al
    Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
    JAMA. 2025 Dec 12:e2524784. doi: 10.1001/jama.2025.24784.
    PubMed         Abstract available
    
    
94. BAXTER NN, Phillips KA
    Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention.
    JAMA. 2025 Dec 12. doi: 10.1001/jama.2025.24817.
    PubMed        
    
    

    
    Mol Ther Oncol

95. PARK N, Jeon SH, Kim Y, Kim S, et al
    Akt inhibition enhances the antitumor efficacy of immune checkpoint blockades and radiotherapy in a syngeneic breast cancer model.
    Mol Ther Oncol. 2025;33:201087.
    PubMed         Abstract available
    
    

    
    N Engl J Med

96. LOIBL S, Park YH, Shao Z, Huang CS, et al
    Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
    N Engl J Med. 2025 Dec 10. doi: 10.1056/NEJMoa2514661.
    PubMed         Abstract available
    
    

    
    Nature

97. PADRAO N, Severson TM, Gregoricchio S, Guijarro A, et al
    Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.
    Nature. 2025 Dec 10. doi: 10.1038/s41586-025-09869.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

98. ZATTARIN E, Marra A, Palazzo A, Griguolo G, et al
    Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.
    NPJ Breast Cancer. 2025 Dec 13. doi: 10.1038/s41523-025-00859.
    PubMed         Abstract available
    
    
99. WANNAPHUT C, Ponvilawan B, Iwase T, Takahashi Y, et al
    Racial and ethnic disparities in survival outcomes among patients with inflammatory breast cancer: a systematic review and meta-analysis.
    NPJ Breast Cancer. 2025 Dec 13. doi: 10.1038/s41523-025-00879.
    PubMed         Abstract available
    
    
100. ALAMUKII NA, Kovacs A, Raghavan S, Ilio J, et al
     Immune-stromal heterogeneity in breast cancer across diverse ancestries: impact on prognosis and treatment response.
     NPJ Breast Cancer. 2025 Dec 12. doi: 10.1038/s41523-025-00881.
     PubMed         Abstract available
     
     
101. SANJARI MOGHADDAM A, Lu KY, Nasrollahi E, Oji L, et al
     Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration.
     NPJ Breast Cancer. 2025 Dec 9. doi: 10.1038/s41523-025-00873.
     PubMed         Abstract available
     
     
102. JACKSON I, Lei X, Zhao H, Murthy R, et al
     Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer.
     NPJ Breast Cancer. 2025;11:138.
     PubMed         Abstract available
     
     
103. VIVARELLI S, Formica T, Puliatti Y, Spatari G, et al
     Night shift work and breast cancer: from etiopathology to precision risk analysis.
     NPJ Breast Cancer. 2025 Dec 4. doi: 10.1038/s41523-025-00863.
     PubMed         Abstract available
     
     
104. IYENGAR NM, O'Shaughnessy JA, Moore HB, Hamilton E, et al
     Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.
     NPJ Breast Cancer. 2025 Dec 4. doi: 10.1038/s41523-025-00864.
     PubMed         Abstract available
     
     
105. GURUNG SK, Berger K, Rao SS
     Cancer cell-monocyte co-culture spheroids recapitulate pro-tumorigenic, immunosuppressive, and drug-resistant microenvironments in brain metastatic breast cancer.
     NPJ Breast Cancer. 2025;11:136.
     PubMed         Abstract available
     
     

     
     Oncology

106. DENNSTADT F, Zink J, Cihoric N, Weder D, et al
     Development of a Rule-Based Knowledge Base for Digitalization of Standard Operating Procedures on Radiotherapy in Breast Cancer.
     Oncology. 2025 Dec 11:1-13. doi: 10.1159/000549853.
     PubMed         Abstract available
     
     

     
     PLoS Biol

107. WANG L, Wu X, Paul A, Yao J, et al
     The deubiquitinating enzyme Cezanne stabilizes BRCA1 by counteracting APC/C and Ube2S-dependent Lys11-linked ubiquitination.
     PLoS Biol. 2025;23:e3003545.
     PubMed         Abstract available
     
     

     
     PLoS One

108. ANBARI A, Massey Z, Adediran A, Wang N, et al
     "This needs to be told to everyone": Content analysis of written immediate responses from an online experiment examining health warning messages about alcohol consumption and breast cancer risk.
     PLoS One. 2025;20:e0338687.
     PubMed         Abstract available
     
     
109. NIZAM AM
     Minimum Displacement in Existing Moment (MDEM)- A new supervised learning algorithm by incrementally constructing the moments of the underlying classes.
     PLoS One. 2025;20:e0336933.
     PubMed         Abstract available
     
     
110. HAQ BU, Sofi S, Qayoom H, Jan N, et al
     Unravelling the therapeutic potential of dual TGFbeta-1 and CXCR4 inhibition in breast cancer using computational strategies.
     PLoS One. 2025;20:e0323665.
     PubMed         Abstract available
     
     
111. GIVI T, Mohajerani F, Tehrankhah ZM, Karimi Taheri M, et al
     Nano-curcumin enhances the sensitivity of tamoxifen-resistant breast cancer cells via the Cyclin D1-DILA1 axis and the PI3K/AKT/mTOR pathway downregulation.
     PLoS One. 2025;20:e0335165.
     PubMed         Abstract available
     
     
112. LIM YC, Lee YJ, Ha IH, Lee YS, et al
     Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study.
     PLoS One. 2025;20:e0335083.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

113. WANG X, Sun J, Lan B, Wang C, et al
     Asparagine endopeptidase prompts breast cancer-related pericardial calcification by regulating IGF2 and integrin alphavbeta5.
     Proc Natl Acad Sci U S A. 2025;122:e2512936122.
     PubMed         Abstract available
     
     
114. REINA J, Vallmajo-Martin Q, Ning J, Michi AN, et al
     LHPP expression in triple-negative breast cancer promotes tumor growth and metastasis by modulating the tumor microenvironment.
     Proc Natl Acad Sci U S A. 2025;122:e2505653122.
     PubMed         Abstract available
     
     

     
     Radiol Imaging Cancer

115. ARLEDGE CA, Zhao AH, Topaloglu U, Zhao D, et al
     Dynamic Contrast-enhanced MRI for Evaluating Breast Cancer Chemotherapy Response Using Conditional Generative Adversarial Networks.
     Radiol Imaging Cancer. 2026;8:e250110.
     PubMed         Abstract available
     
     

     
     Radiology

116. EOM HJ, Cha JH, Cho SM, Kim HJ, et al
     Interreader Agreement and Diagnostic Confidence in Discriminating Masses and Nonmass Lesions at Breast US.
     Radiology. 2025;317:e250783.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.